Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Narinder Bhalla"'
Publikováno v:
Current Therapeutic Research, Vol 95, Iss , Pp 100651- (2021)
Externí odkaz:
https://doaj.org/article/41f3caec94d941fcbfcba3848b32f9b8
Autor:
Eric Wittbrodt, Narinder Bhalla, Karolina Andersson Sundell, Qi Gao, Liyan Dong, Matthew A. Cavender, Phillip Hunt, Nathan D. Wong, Carl Mellström
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 3, Pp n/a-n/a (2020)
Abstract Background THEMIS (NCT01991795) showed that in patients with type 2 diabetes (T2D) and stable coronary artery disease (CAD) but with no prior myocardial infarction (MI) or stroke, ticagrelor plus acetylsalicylic acid (ASA) decreased the inci
Externí odkaz:
https://doaj.org/article/1bd8efb6f17a42dfa632a3776559227b
Autor:
Jacob A. Doll, Lisa A. Kaltenbach, Kevin J. Anstrom, Christopher P. Cannon, Timothy D. Henry, Gregg C. Fonarow, Niteesh K. Choudhry, Eileen Fonseca, Narinder Bhalla, James M. Eudicone, Eric D. Peterson, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background Hospitals commonly provide a short‐term supply of free P2Y12 inhibitors at discharge after myocardial infarction, but it is unclear if these programs improve medication persistence and outcomes. The ARTEMIS (Affordability and Real‐Worl
Externí odkaz:
https://doaj.org/article/a86cb2e7179048ca8323fa7e3710c7ed
Autor:
Robert W. Yeh, Eric A. Secemsky, Kamil F. Faridi, John Venditto, Eileen Fonseca, Narinder Bhalla, Naeem D. Khan, Thomas Wilson, Nipun Atreja, Changyu Shen
Publikováno v:
The American Journal of Cardiology. 151:70-77
Heart failure (HF) is common in patients presenting with acute myocardial infarction (MI), but incidence and predictors of new onset HF after hospitalization for MI are less well characterized. We evaluated patients hospitalized for acute MI without
Autor:
Charles L Johnson, Alex Frost, Durgesh Bhandary, Narinder Bhalla, Deborah B. Diercks, Sripal Bangalore, John F. Heitner, Naeem D. Khan, W. Frank Peacock, Sunil V. Rao, Renato Derita, Charles V. Pollack, Steven H. Silber
Publikováno v:
Critical Pathways in Cardiology
Objective: To describe from a noninterventional registry (Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Acute Coronary Syndrome), the short-term ischemic and hemorrhagic outcomes in patients with non-ST elevation myoc
Autor:
Narinder Bhalla, Donna Zarzuela
Publikováno v:
Current Therapeutic Research, Vol 95, Iss, Pp 100651-(2021)
Current Therapeutic Research, Clinical and Experimental
Current Therapeutic Research, Clinical and Experimental
Autor:
Marc P. Bonaca, Eva Lesén, Evangelos Giannitsis, Tomas Jernberg, Aldo Pietro Maggioni, Albert Ariza-Solé, Jurrien M. Ten Berg, Narinder Bhalla, Robert F. Storey
Publikováno v:
Journal of the American College of Cardiology. 79:1140
Autor:
David Cobden, John Venditto, Tope Olufade, Naeem D. Khan, Nipun Atreja, Durgesh Bhandary, Narinder Bhalla
Publikováno v:
Circulation. 142
Background: Current guidelines recommend ticagrelor over clopidogrel as part of DAPT regimen for ACS treatment. However, real-world head-to-head assessment of ticagrelor and clopidogrel has been methodologically challenging due to prescribing pattern
Autor:
Daniel A. Belletti, David Cobden, Durgesh Bhandary, Nipun Atreja, Naeem D. Khan, Narinder Bhalla
Publikováno v:
The American journal of managed care. 26
Innovative value strategies for reimbursement of medications include value-based agreements (VBAs) between payers and pharmaceutical manufacturers, which have the potential to improve affordability and patient access to therapy, as well as lead to a
Autor:
Narinder Bhalla, Phillip Hunt, Carl Mellström, Nathan D. Wong, Karolina Andersson Sundell, Eric Wittbrodt, Marco Kuster
Publikováno v:
Journal of diabetes and its complications. 35(4)
Aims THEMIS ( NCT01991795 ) demonstrated cardioprotective benefits of ticagrelor plus acetylsalicylic acid (ASA) compared with placebo plus ASA in patients with type 2 diabetes (T2D), stable coronary artery disease (CAD) and no history of myocardial